Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review

References

• Tilki D, Mandel P, Schlomm T, et al. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. J Urol. 2015;193:1970–1975.
   PubMed Web of Science ®Google Scholar
• Parker WP, Davis BJ, Park SS, et al. Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol. 2017;71:340–348.
   PubMed Web of Science ®Google Scholar
• Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–237.
   PubMed Web of Science ®Google Scholar
• Devos G, De Meerleer G, Joniau S. Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? Eur Urol. 2019;76:265–267.
   PubMed Web of Science ®Google Scholar
• Mottet N, Briers E, Cornford P, et al. Prostate cancer guidelines. 2019. Available from: https://uroweb.org/guideline/prostate-cancer/
   Google Scholar
• Ost P, Decaestecker K, Lambert B, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014;74:297–305.
   PubMed Web of Science ®Google Scholar
• Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652–1659.
   PubMed Web of Science ®Google Scholar
• Ploussard G, Almeras C, Briganti A, et al. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol. 2015;194:983–988.
   PubMed Web of Science ®Google Scholar
• Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852–863.
   PubMed Web of Science ®Google Scholar
• Steuber T, Jilg C, Tennstedt P, et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus. 2019;5:1007–1013.
   PubMedGoogle Scholar
• NCCN Guidelines Prostate Cancer. 2019. Version 4. 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Calais J, Ceci F, Eiber M, et al. (18)F-Fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–1294.
   PubMed Web of Science ®Google Scholar
• Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–937.
   PubMed Web of Science ®Google Scholar
• Muller J, Ferraro DA, Muehlematter UJ, et al. Clinical impact of (68)Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging. 2019;46:889–900.
   PubMed Web of Science ®Google Scholar
• Ferraro DA, Muehlematter UJ, Garcia Schuler HI, et al. (68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:147–159.
   PubMed Web of Science ®Google Scholar
• Fossati N, Suardi N, Gandaglia G, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol. 2019;75:176–183.
   PubMed Web of Science ®Google Scholar
• van Kalmthout LWM, van Melick HHE, Lavalaye J, et al. Prospective validation of gallium-68 PSMA-PET/CT in primary staging of prostate cancer patients. J Urol. 2019;203.
   Google Scholar
• Panje C, Zilli T, Pra AD, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019;14:177.
   PubMed Web of Science ®Google Scholar
• Lancia A, Zilli T, Achard V, et al. Oligometastatic prostate cancer: the game is afoot. Cancer Treat Rev. 2019;73:84–90.
   PubMed Web of Science ®Google Scholar
• Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650.
   PubMed Web of Science ®Google Scholar
• Pasqualetti F, Panichi M, Sollini M, et al. (18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:185–191.
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–453.
   PubMed Web of Science ®Google Scholar
• Siva S, Bressel M, Murphy DG, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74:455–462.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Fanetti G, Fodor C, et al. Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer. 2017;15:e623–e632.
   PubMed Web of Science ®Google Scholar
• Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014;9:135.
   PubMed Web of Science ®Google Scholar
• Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–897.
   PubMed Web of Science ®Google Scholar
• Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49–55.
   PubMed Web of Science ®Google Scholar
• Kneebone A, Hruby G, Ainsworth H, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1:531–537.
   PubMed Web of Science ®Google Scholar
• Soldatov A, von Klot CAJ, Walacides D, et al. Patterns of progression after 68Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2019;103:95–104.
   PubMed Web of Science ®Google Scholar
• Supiot S, Pasquier D, Buthaud X, et al. Oligopelvis-GETUG P07: a multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses of prostate cancer. J Clin Oncol. 2020;38:93–93.
   Web of Science ®Google Scholar
• Tran S, Jorcano S, Falco T, et al. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41:960–962.
   PubMed Web of Science ®Google Scholar
• Fodor A, Berardi G, Fiorino C, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU Int. 2017;119:406–413.
   PubMed Web of Science ®Google Scholar
• Lepinoy A, Silva YE, Martin E, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:40–48.
   PubMed Web of Science ®Google Scholar
• Jethwa KR, Hellekson CD, Evans JD, et al. 11C-Choline PET guided salvage radiation therapy for isolated pelvic and paraortic nodal recurrence of prostate cancer after radical prostatectomy: rationale and early genitourinary or gastrointestinal toxicities. Adv Radiat Oncol. 2019;4:659–667.
   PubMedGoogle Scholar
• Moher D, Shamseer L, Clarke M, et al.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Murphy DG, Sweeney CJ, Tombal B. “Gotta Catch 'em All”, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol. 2017;72:1–3.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–836.
   PubMed Web of Science ®Google Scholar
• De Bleser E, Willems R, Decaestecker K, et al. A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer. Cancers (Basel). 2020;12:132.
   Web of Science ®Google Scholar
• Ingrosso G, Trippa F, Maranzano E, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35:45–49.
   PubMed Web of Science ®Google Scholar
• Lepinoy A, Cochet A, Cueff A, et al. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. Radiother Oncol. 2014;111:120–125.
   PubMed Web of Science ®Google Scholar
• Muldermans JL, Romak LB, Kwon ED, et al. Stereotactic body radiation therapy for oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2016;95:696–702.
   PubMed Web of Science ®Google Scholar
• Ost P, Jereczek-Fossa BA, Van As N, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28:e115–20.
   PubMed Web of Science ®Google Scholar
• Ponti E, Ingrosso G, Carosi A, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13:e279–e284.
   PubMed Web of Science ®Google Scholar
• Triggiani L, Alongi F, Buglione M, et al. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer. 2017;116:1520–1525.
   PubMed Web of Science ®Google Scholar
• Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, et al. Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET/CT. Clin Genitourin Cancer. 2017;15:e773–e782.
   PubMed Web of Science ®Google Scholar
• Detti B, Bonomo P, Masi L, et al. Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World J Urol. 2015;33:1197–1203.
   PubMed Web of Science ®Google Scholar
• Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12.
   PubMed Web of Science ®Google Scholar
• Pasqualetti F, Panichi M, Sainato A, et al. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11:9.
   PubMed Web of Science ®Google Scholar
• Vaugier L, Palpacuer C, Rio E, et al. Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2019;103:1061–1067.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–2058.
   PubMed Web of Science ®Google Scholar
• Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81–89.
   PubMed Web of Science ®Google Scholar
• Vilela RA, Navarro NF, Faria ET, et al. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: a systematic review. J Med Imaging Radiat Oncol. 2018;62:692–706.
   PubMed Web of Science ®Google Scholar
• Budaus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393–396.
   PubMed Web of Science ®Google Scholar
• Rischke HC, Schultze-Seemann W, Wieser G, et al. Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol. 2015;191:310–320.
   PubMed Web of Science ®Google Scholar
• Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52:1622–1628.
   PubMed Web of Science ®Google Scholar
• Wurschmidt F, Petersen C, Wahl A, et al. [18F]Fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44.
   PubMed Web of Science ®Google Scholar
• Supiot S, Rio E, Pacteau V, et al. OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer. 2015;15:646.
   PubMed Web of Science ®Google Scholar
• Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383–387.
   PubMed Web of Science ®Google Scholar
• Harris VA, Staffurth J, Naismith O, et al.; PIVOTAL Trialists. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:874–883.
   PubMed Web of Science ®Google Scholar
• De Bruycker A, De Bleser E, Decaestecker K, et al. Nodal oligorecurrent prostate cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates. Eur Urol. 2019;75:826–833.
   PubMed Web of Science ®Google Scholar
• Aizer AA, Yu JB, McKeon AM, et al. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. 2009;75:1344–1349.
   PubMed Web of Science ®Google Scholar
• Tharmalingam H, Choudhury A, Van Herk M, et al. New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. Nat Rev Urol. 2019;16:523–538.
   PubMed Web of Science ®Google Scholar
• Franzese C, Fogliata A, D'Agostino GR, et al. Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. J Cancer Res Clin Oncol. 2017;143:1301–1309.
   PubMed Web of Science ®Google Scholar
• Jorgo K, Polgar C, Major T, et al. Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. a single institution, prospective study. Pathol Oncol Res. 2019.
   PubMed Web of Science ®Google Scholar
• Sini C, Noris Chiorda B, Gabriele P, et al. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: first quantification of bowel dose-volume effects. Radiother Oncol. 2017;124:296–301.
   PubMed Web of Science ®Google Scholar
• De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76:732–739.
   PubMed Web of Science ®Google Scholar
• De Bruycker A, Spiessens A, Dirix P, et al. PEACE V – salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20:406.
   PubMed Web of Science ®Google Scholar
• Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58:3–10.
   PubMed Web of Science ®Google Scholar
• De Bruycker A, Lambert B, Claeys T, et al. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int. 2017;120:815–821.
   PubMed Web of Science ®Google Scholar
• Graziani T, Ceci F, Castellucci P, et al. C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016;43:1971–1979.
   PubMed Web of Science ®Google Scholar
• Lieng H, Hayden AJ, Christie DRH, et al. Radiotherapy for recurrent prostate cancer: 2018 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2018;129:377–386.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508–547.
   PubMed Web of Science ®Google Scholar
• Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17:747–756.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–428.
   PubMed Web of Science ®Google Scholar
• Pollack A, Balogh AG, Low D, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: the NRG Oncology/RTOG 0534 SPPORT trial. ASTRO. 2018;102:1605.
   Google Scholar
• Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, et al. Prostate-specific membrane antigen positron emission tomography-detected oligorecurrent prostate cancer treated with metastases-directed radiotherapy: role of addition and duration of androgen deprivation. Eur Urol Focus. 2019.
   PubMedGoogle Scholar
• Ploussard G, Gandaglia G, Borgmann H, et al. Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review. Eur Urol. 2019;76:493–504.
   PubMed Web of Science ®Google Scholar
• Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One. 2013;8:e69239.
   PubMed Web of Science ®Google Scholar
• Huang F, Wu G, Yang K. Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol. 2014;9:230.
   PubMed Web of Science ®Google Scholar
• Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6:e28650.
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13–24.
   PubMed Web of Science ®Google Scholar
• Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992–2003.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–131.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700.
   PubMed Web of Science ®Google Scholar